-
Track & Monitor
Innovation in Pharmaceuticals: Platinum as active pharmaceutical ingredient
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Platinum as active pharmaceutical ingredient segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – EGT-101 in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome )
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - EGT-101 in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome ) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data.EGT-101 in Mucopolysaccharidosis III (MPS III) (Sanfilippo Syndrome...
-
Sector Analysis
Mergers and Acquisitions (M&A) in the Contract Manufacturing Industry – Implications and Outlook – 2023 Edition
M and A In Pharmaceutical Contract Manufacturing Industry Report Overview During 2018–22, contract manufacturing organization (CMO) merger and acquisition (M&A) deal activity increased, and the targeted manufacturers have adopted specialized capabilities such as controlled substance and containment manufacture. Despite considerable macroeconomic challenges for pharma manufacturers, 2021–22 witnessed strong M&A activity and CMO valuations, although there was a slight decline in CMO M&A activity in 2022 due to rising inflation and interest rates. The Mergers and Acquisitions (M&A) in the Contract...
-
Track & Monitor
Chemotherapy in Pharmaceuticals: Platinum-based cancer drug compositions
Our team of industry experts has meticulously researched and analyzed the latest trends, innovations and emerging technologies in the Pharmaceuticals industry’s Platinum-based cancer drug compositions segment. By leveraging our report, you will gain invaluable insights that can revolutionise your business strategies and give you a competitive edge. Note: This is an “on-demand” report and will be delivered within 2 to 4 business days (excluding weekends and holidays) of the purchase. Certain sections in the report may be removed or altered...
-
Company Profile
Esteve Pharmaceuticals SA – Company Profile
Esteve Pharmaceuticals SA (Esteve) researches, develops, and markets prescription and generic pharmaceuticals. The company's product portfolio encompasses innovative prescription drugs, over the counter (OTC) pharmaceuticals and generic drugs. It offers drugs in central nervous system, infection, respiratory, cardiovascular, cancer, primary care, and other therapeutic areas. Esteve also provides customized contract manufacturing services of active pharmaceutical ingredients (APIs) and advanced intermediates for the global pharmaceutical industry. The company markets its products to pharmaceutical companies, healthcare facilities and other customers through licensing...
Add to Basket -
Product Insights
Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update
Alpha N-Acetylglucosaminidase (NAGLU) Drugs in Development Report Overview Alpha-N-acetylglucosaminidase is a protein enzyme located in lysosomes compartments within cells that digest and recycle different types of molecules. The Alpha N-Acetylglucosaminidase (N Acetyl Alpha Glucosaminidase or NAGLU or EC 3.2.1.50) drugs in development research report provides comprehensive information on the therapeutics under development for Alpha N-Acetylglucosaminidase. The report also analyzes the stage of development, mechanism of action (MoA), route of administration (RoA), molecule type, therapy area, and indication. The pipeline report...